News Insilico ends 2025 with $293m Hong Kong IPO One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
News Boehringer bags FDA okay for new pulmonary fibrosis drug Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?
News PureTech launches lung disease specialist Celea PureTech launches Celea Therapeutics, tasked with bringing forward a drug that could offer a 'step change' in pulmonary fibrosis treatment.
News Pliant slumps on decision to pause lung disease drug trial Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.
News Trial sets up filings for Boehringer IPF drug nerandomilast With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
Patients Chronic cough and the patient voice Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ lives.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.